SB-17170

N/A

Report date: 2025/02/07 15:07:16
NME

Base Information

Drug NameSB-17170
Drug Alias NameSB-17170
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHigh Mobility Group Protein B1 inhibitors
TargetsHigh Mobility Group Protein B1
Therapy Area/IndicationsSolid tumoursDrug-Related Side Effects and Adverse ReactionsIdiopathic Pulmonary Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSpark Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesSpark Biopharma IncSeoul National University
Inactive CompaniesN/A
Active IndicationsSolid tumoursDrug-Related Side Effects and Adverse ReactionsIdiopathic Pulmonary Fibrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A